Main Article Content
Aim: This study evaluated the effect of Ganoderma lucidum on selected biochemical indices for cardiometabolic risk.
Study Design: Case-control study.
Place and duration of Study: This study was carried out in the Department of Medical Laboratory Science, Babcock University between December, 2018-May, 2019.
Methods: The study included 32 female guinea pigs which were assigned into 4 groups (A-D) with 8 in each group. Group A animals served as control, group B animals received only monophasic combined oral contraceptives (COC), group C animals received monophasic COC and 50mg/kg of G. lucidum, group D animals received monophasic COC and 100 mg/kg of G. lucidum. All the test animals received their treatment once daily through oral gavage for 12 weeks. All animals were sacrificed 24 hours after the last dose was given to the test groups. Blood sample was collected via cardiac puncture. Lipoprotein-associated phospholipase-A2 (Lp-PLA2), high sensitive C reactive protein (hsCRP), insulin, insulin-like growth factor-1 (IGF-1), fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) were determined using spectrophotometric methods and ELISA as appropriate. HOMA-IR was calculated using homeostasis model assessment index. Data obtained were statistically analyzed using ANOVA, post hoc, all values were expressed as mean±standard deviation. P value less than 0.05 was considered significant.
Results: We observed that groups B (25%) and C (25%) animals had significantly higher levels of hsCRP, LpPLA2, TC, TG, LDL, FBG, IGF-1 and HOMA-IR when compared with groups A (25%) and D animals (25%) (p<0.05), however there was no significant statistical difference when groups B and C were compared. Also we observed higher levels of HDL in groups C and D animals when compared with groups A and B animals but not significant statistically.
Conclusion: The use of G. lucidum stymies the development of COC-induced cardiometabolic syndrome in a dose-dependent manner.
Okafor CI. The metabolic syndrome in Africa: Current trends. Indian Journal of Endocrinology and Metabolism. 2012;16(1): 56-66.
Song Qing, Wang Shaoshan, Zafari Mazair. Genetics of metabolic syndrome. Hospital Physician. 2006;51-61.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009;20:1640-1645.
O’Neill S, O’Driscoll L. Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. Obesity Reviews. 2015;16:1-12.
Srivastava AK. Challenges in the treatment of cardiometabolic syndrome. Indian J. Pharmacol. 2012;44(2):155-156.
Wei W, Li Y, Chen F, Chen C, Sun T, Sun Z, et al. Dyslipidaemia, combined oral contraceptives use and their interaction on the risk of hypertension in Chinese women. J Hum Hypertens. 2011;25:364–371.
Olatunji LA, Michael OS, Adewumi FO, Aiyegboyin IJ, Olatunji VA. Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. Pathophysiology. 2012;19: 29-34.
Chukwubike UO, Solomon AB, Benjamin N, Roseanne O, Pascal C, Adebayo A, Ngozika B. Comparative effects of Injectable and oral hormonal contracep-tives on lipid profiles. Eur J Cardvs Med. 2011;2(1):20-22.
Matfin G. Challenges in developing therapies for the metabolic syndrome. British Journal of Diabetes and Vascular Disease. 2008;7:152.
Longo-Mbenza B, Mvindu HN, On’kin JBK, Bikuku N, Phanzu BK, et al. The deleterious effects of physical inactivity on elements of insulin resistance and metabolic syndrome in Central Africans at high cardiovascular risk. Diabetes and Metabolic syndrome: Clinical Research and Reviews. 2011;5:1-6.
Huang CY, Chen JYF, Wu JE. Ling-zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells. Journal of Agricultural and Food Chemistry. 2010; 58(15):8798–8805.
Zhang HN, Lin ZB. Effect and mechanism of Ganoderma lucidum polysaccharide on autoimmune diabetic mice. National Medical Journal of China. 2003;83(22): 1999–2000.
Berger A, et al. Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs. Lipids in Health and Disease. 2004;3(2).
Paterson RR. Ganoderma - A therapeutic fungal biofactory. Phytochemistry. 2006; 67(731):1985-2001.
Bal C. Antioxidant and antimicrobial capacities of Ganoderma lucidum. J Bacteriol Mycol Open Access. 2019:7(1): 5‒7.
Ojiako AO, Chikezie PC, Zedech UC. Serum lipid profile of hyperlipidaemic rabbits (Lepus townsendii) administered with leaf extracts of Hibiscus rosesinesis, Emilia coccinea, Acanthus montanus and Asystasia gangetica. J Med Plant Res. 2013;7:3226-3231.
Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
Kaur JA. Comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;943162.
Emokpae MA, Udia PO, Osadolor HB. Effect of duration of use of hormonal contraceptive pills on total lipid and lipoproteins in Nigerian women. Int. J. Pharma Bio. 2010;1(3).
Mahmood Isam H, Ali Hanaan J. Effect of hormonal contraceptives on prevalence of metabolic syndrome in women. Rawan Medical Journal. 2012;37(2).
George Asare, Shiela Santa, Robert A Ngala, Bernice Asiedu, Daniel Afriye, Albert Amoah. Effect of hormonal contraceptives on lipid profile and the risk of cardiovascular disease in a Ghanaian Community. International Journal of Women’s Health. 2014;6:597-603.
Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004;103:927–933.
Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol. 2007;109: 761–777.
Cauci Sabina, Manuela Di Santolo, Jennifer F. Culhane, Giuliana Stel, Fabio Gonano, Secondo Guaschino. Effects of third-generation oral contraceptives on high-sensitivity c-reactive protein and homocysteine in young women. Obs & Gny. 2008;111(4):857-864.
Sabina Cauci, Maria Pia Francescato, Francesco Curcio. Combined oral contraceptives increase high-sensitivity c-reactive protein but not haptoglobin in female athletes. Sports Med; 2016.
Acevedo M, Varleta P, Kramer V, Quiroga T, Prieto C, Prada J, Navarrete C. Lipoprotein associated phospholipase A2 and C- reactive protein as predictors of metabolic syndrome in subjects without cardiovascular disease. Eurheart J. 2013; 34(Suppl.1):P701.
vanRooijen M, Hansson LO, Frostega˚rd J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contracep-tives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006;4:77–82.
Frempong BA, Ricks M, Sen S, Sumner A. E. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. Journal of Clinical Endocrinology and Metabolism. 2008; 93(6):2097–2103.
Rickenlund A, Thoren M, Nybacka A, Frystyk J, Linden Hirschberg A. Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbances. Human Reproduction. 2010; 1:85-93.
Friedrich A, Ludwig AK, Jauch-Chara K, Loebig M, Rudolf S, Tauchert S, Diedrich K, Schweiger U, Oltmanns KM. Oral contraception enhances growth hormone responsiveness to hyper- and hypogly-caemia. Diabetic Medicine. 2012;29:345–50.
Sitruk-Ware, Regine, Anita Nath. Characteristics and metabolic effects of oestrogen and progestins contained in oral contraceptive pills. Best Practice and Research Clinical Endocrinology and Metabolism. 2013;27:13-24.
Berenson AB, van den Berg P, Williams KJ, Mahbubur R. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstetrics and Gynaecology. 2011; 117(1):41–47.
Hassan EE, Ibrahim EYM, Shrif NMA, Modawe G. Effect of low-dose oral contraceptives on lipid profile levels in Sudanese women using oral contraceptive pills. Sudan Journal of Medical Sciences. 2014;9(2):1-12.
Naz F, Jyoti S, Akhtar N, Afzal M, Siddique YH. Lipid profile of women using oral contraceptive pills. Pakistan Journal of Biological Sciences. 2012;15(19):947-950.
Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Järvelin MR, Pouta A. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol. 2008; 199:529-539.
Taneepanichskul S, Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecological Endocrinology. 2007;23: 347–350.
Meng G, Zhu H, Yang S, Wu F, Zheng H, Chen E, Xu J. Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotosin-induced diabetic rats. Carbohydrate Polymers. 2011;84:180-185.
Hüseyin Avni Eroğlu, Ebru Beytut. Effect of Ganoderma lucidum polysaccharides on oxidative damage in liver of STZ-diabetic rats. Biomedical Research. 2018;29(18): 3436-3443.
Kar-Lok Wong, Hung-Hsing Chao, Paul Chan, Li-Ping Chang, Chi-Feng Liu. Antioxidant activity of Ganoderma lucidum in acute ethanol-induced heart toxicity. Phytother. Res. 2004;18:1024–1026.